The patent, EP3170904, "Compositions and methods for nucleic acid sequencing," is the second PacBio patent revoked by the EPO this year.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
In a retrospective analysis, UK researchers found that long-read sequencing of HLA genes in stem cell transplantation donors and recipients led to better outcomes.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
PacBio agreed to pay attorneys' fees to settle lawsuits brought against it by investors regarding Illumina's acquisition.
Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
The company is developing a single-molecule sequencing technology intended to significantly reduce the cost and improve the accuracy of sequencing.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.